OraSure Technologies, Inc. (OSUR)

NASDAQ: OSUR · IEX Real-Time Price · USD
5.78
+0.03 (0.52%)
Mar 24, 2023, 4:00 PM EDT - Market closed
0.52%
Market Cap 423.35M
Revenue (ttm) 387.48M
Net Income (ttm) -17.93M
Shares Out 73.24M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 607,655
Open 5.69
Previous Close 5.75
Day's Range 5.49 - 5.84
52-Week Range 2.62 - 7.26
Beta 0.09
Analysts Buy
Price Target 5.99 (+3.63%)
Earnings Date May 9, 2023

About OSUR

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebol... [Read more]

Sector Healthcare
IPO Date Nov 12, 1986
Employees 785
Stock Exchange NASDAQ
Ticker Symbol OSUR
Full Company Profile

Financial Performance

In 2022, OSUR's revenue was $387.48 million, an increase of 65.82% compared to the previous year's $233.67 million. Losses were -$17.93 million, -22.02% less than in 2021.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for OSUR stock is "Buy." The 12-month stock price forecast is $5.99, which is an increase of 3.63% from the latest price.

Price Target
$5.99
(3.63% upside)
Analyst Consensus: Buy
Stock Forecasts

News

3 Low-Beta Stocks to Buy to Combat the Volatile Market

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. OraSure Technologies (OSUR), Compa?

Other symbols: BVNVIPS
4 days ago - Zacks Investment Research

Surging Earnings Estimates Signal Upside for OraSure (OSUR) Stock

OraSure (OSUR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

1 month ago - Zacks Investment Research

OraSure Technologies (OSUR) Surpasses Q4 Earnings and Revenue Estimates

OraSure (OSUR) delivered earnings and revenue surprises of 2,000% and 26.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability

InteliSwab ® revenue of $88.9 million in Q4, up 12% sequentially; wins two new federal government contracts extending the tail on InteliSwab ® revenue

1 month ago - GlobeNewsWire

2022 Fourth Quarter Earnings Conference Call Tuesday, February 14, 2023, 5:00 p.m. ET

BETHLEHEM, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth quarter financial results and certai...

1 month ago - GlobeNewsWire

OraSure Technologies Continues its Dedication to Ending the HIV Epidemic

Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS Day Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS Day

4 months ago - GlobeNewsWire

OraSure Technologies to Present at Stephens Annual Investment Conference

BETHLEHEM, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytic...

4 months ago - GlobeNewsWire

OraSure Technologies (OSUR) Q3 Earnings and Revenues Top Estimates

OraSure (OSUR) delivered earnings and revenue surprises of 216.67% and 26.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

OraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year

InteliSwab® revenue of $79.6 million in Q3, up 85% sequentially; Company continues to expand test production capacity

4 months ago - GlobeNewsWire

OraSure Technologies Receives General Clearance for its ORAcollect®•Dx Device for Over-the Counter (OTC) Use from the U.S. Food and Drug Administration (FDA)

FDA Clearance Received Through Partnership with Grifols to Support Screening for Risk of Alpha1- Antripsyn Deficiency (Alpha-1) in U.S. Adult Population

5 months ago - GlobeNewsWire

InteliSwab® COVID-19 Rapid Test Now Available in Amazon's Online Store

BETHLEHEM, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced ...

5 months ago - GlobeNewsWire

2022 Third Quarter Earnings Conference Call Tuesday, November 8, 2022, 5:00 p.m. ET

BETHLEHEM, Pa., Nov. 01, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 third quarter financial results and certain...

5 months ago - GlobeNewsWire

3 Penny Stocks That Are Too Cheap to Ignore

The traditional definition of penny stocks is those companies whose shares trade for $5 or less. It's never easy finding cheap penny stocks to buy amongst this oppressed group because they are often s...

Other symbols: ARLO
6 months ago - InvestorPlace

OraSure Technologies Receives $8.6 Million BARDA Contract to Develop 2nd Generation Ebola Test

BETHLEHEM, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced...

6 months ago - GlobeNewsWire

OraSure Wins Contract to Supply “Together Take Me Home,” HIV Self-Testing Initiative Sponsored by the Centers for Disease Control and Prevention

The effort promotes HIV testing and awareness in populations disproportionately affected by HIV The effort promotes HIV testing and awareness in populations disproportionately affected by HIV

6 months ago - GlobeNewsWire

OraSure Partners with Mars Petcare in One of the Largest Ever Microbiome Studies to Evaluate Pet Health

BETHLEHEM, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced...

6 months ago - GlobeNewsWire

OraSure Technologies (OSUR) Reports Break-Even Earnings for Q2

OraSure (OSUR) delivered earnings and revenue surprises of 100% and 13.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

OraSure Reports 2Q22 Record Revenue of $80.2 Million Growing 39% Year-Over-Year

InteliSwab ® revenue of $43.1 million in Q2, up 95% sequentially with significant scaling in production

8 months ago - GlobeNewsWire

OraSure Technologies to Hold 2022 Second Quarter Earnings Conference Call Tuesday, August 9, 2022, 5:00 p.m. ET

BETHLEHEM, Pa., Aug. 02, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 second quarter financial results and certai...

8 months ago - GlobeNewsWire

OraSure's Ongoing Commitment to End the Hepatitis C Epidemic Heats Up at the Racetrack

Race to End Hep C initiative demonstrates the ability of easy-to-administer, low-cost testing solutions to identify patients and direct them to appropriate care Race to End Hep C initiative demonstrat...

8 months ago - GlobeNewsWire

OraSure Technologies Launches New Product for Microbiome Researchers to Study DNA and RNA

BETHLEHEM, Pa., July 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced ...

9 months ago - GlobeNewsWire

OraSure Technologies Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BETHLEHEM, Pa., June 08, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced ...

10 months ago - GlobeNewsWire

InteliSwab® COVID-19 Rapid Test Selected by Federal Government for Nationwide School Testing

The rapid at-home COVID-19 test is authorized for ages 2 and up The rapid at-home COVID-19 test is authorized for ages 2 and up

10 months ago - GlobeNewsWire

Carrie Eglinton Manner Appointed Chief Executive Officer of OraSure

Company Concludes Strategic Alternative Process Given Market Conditions and its Belief in its Ability to Build on Recent Operational Success Company Concludes Strategic Alternative Process Given Marke...

10 months ago - GlobeNewsWire

InteliSwab® COVID-19 Rapid Test Validated to Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants

BETHLEHEM, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced t...

11 months ago - GlobeNewsWire